跳至主要内容
临床试验/JPRN-jRCTs042180119
JPRN-jRCTs042180119已完成2 期

A feasibility study of intensity modulated radiotherapy with chemotherapy for locally advanced non-small-cell lung cancer

Harada Hideyuki0 个研究点目标入组 22 人开始时间: 2019年3月19日最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
22

研究概览

简要总结

The primary endpoint for tolerability of chemoradiotherapy with intensity-modulated radiotherapy could not be achieved. However, intensity-modulated radiotherapy could be completed in all but one case, demonstrating good survival and safety.

研究设计

研究类型
Interventional

入排标准

年龄范围
>= 20age old 至 < 75age old(—)
性别
All

入选标准

  • 1)Non-small cell lung cancer(NSCLC) diagnosed by cytological or histological examination
  • 2)Inoperable
  • 3)Clinical stage 3 NSCLC, possible for definitive radiotherapy
  • 4)No previous chemotherapy or radiotherapy
  • 5)Measurable lesions
  • 6)Age; 20 -75 years old
  • 7)ECOG performance status:0-1
  • 8)Ingestible
  • 9)Sufficient function in bone marrow, heart, lung, liver and kidney
  • 10)Written informed consent

排除标准

  • 1)Active double cancer
  • 2)Severe infection or morbidity
  • 3)HBs antigen positive
  • 4)Previous thoracic radiotherapy
  • 5)Interstitial pneumonia or fibrosis on CT
  • 6)Severe emphysema or chronic bronchitis or asthma
  • 7)Severe drug allergy
  • 8)Severe diabetes
  • 9)Unstable angina or myocardial infarction within 6 months
  • 10)Febrile more than or equal to 38 degree
  • 11)Systemic use of corticosteroid or immunosuppressive drug
  • 12)Expectant mother or breast feeding woman or not agreed with contraception
  • 13)Psychiatric disorder
  • 14)Unsuitable for enrollment judged by attending physician

研究者

发起方
Harada Hideyuki

相似试验

IMRT feasibility study for stage III NSCLC | 临床试验